Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago. These ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...

The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million. For the year, the company reported a ...

VOYAGER THERAPEUTICS ($VYGR) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting revenue ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ...

Voyager Therapeutics (VYGR) said on Monday that the company provided positive topline data from its early stage trial of VY7523, an antibody to selectively inhibit the spread of pathological tau in ...

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report released on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Elanco Animal Health (ELAN – Research ...